Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine and Kuvan in Treatment Resistant Schizophrenia
NCT04054973Phase 2Withdrawn
- Sponsor
- University of Massachusetts
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of sapropterin, arginine in schizophrenia, schizoaffective disorder, sponsored by University of Massachusetts. Planned start Sep 2019; status: withdrawn.
02
Drugs
sapropterinarginine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04054973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054973.